[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022004523A - Formulaciones de liberacion controlada para sustancias fisiologicamente activas altamente lipofilicas. - Google Patents

Formulaciones de liberacion controlada para sustancias fisiologicamente activas altamente lipofilicas.

Info

Publication number
MX2022004523A
MX2022004523A MX2022004523A MX2022004523A MX2022004523A MX 2022004523 A MX2022004523 A MX 2022004523A MX 2022004523 A MX2022004523 A MX 2022004523A MX 2022004523 A MX2022004523 A MX 2022004523A MX 2022004523 A MX2022004523 A MX 2022004523A
Authority
MX
Mexico
Prior art keywords
physiologically active
active substances
controlled release
highly lipophilic
release formulations
Prior art date
Application number
MX2022004523A
Other languages
English (en)
Inventor
Annette Grave
Mirko Nowak
Jay Jesko Nowak
Monika Wentzlaff
Sarah Barthold
Christian Geugelin
Original Assignee
Add Advanced Drug Delivery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Add Advanced Drug Delivery Tech Ltd filed Critical Add Advanced Drug Delivery Tech Ltd
Publication of MX2022004523A publication Critical patent/MX2022004523A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se relaciona a una forma de dosis sólida que comprende una matriz con una o más sustancias fisiológicamente activas altamente lipofílicas, uno o más aglutinantes solubles en agua y, con relación al peso de todos los componentes, no más de 20% en peso de las otras sustancias auxiliares.
MX2022004523A 2019-10-16 2020-10-16 Formulaciones de liberacion controlada para sustancias fisiologicamente activas altamente lipofilicas. MX2022004523A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19203580.6A EP3808341A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
PCT/EP2020/079248 WO2021074403A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Publications (1)

Publication Number Publication Date
MX2022004523A true MX2022004523A (es) 2022-09-19

Family

ID=68281185

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004523A MX2022004523A (es) 2019-10-16 2020-10-16 Formulaciones de liberacion controlada para sustancias fisiologicamente activas altamente lipofilicas.

Country Status (10)

Country Link
US (1) US20240139215A1 (es)
EP (2) EP3808341A1 (es)
JP (1) JP2022553653A (es)
CN (1) CN114945353A (es)
AU (1) AU2020365443A1 (es)
BR (1) BR112022006643A2 (es)
CA (1) CA3157654A1 (es)
IL (1) IL292018A (es)
MX (1) MX2022004523A (es)
WO (1) WO2021074403A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3808336A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
EP3001812B1 (en) 2013-10-29 2016-11-02 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
DE102014213548A1 (de) * 2014-07-11 2016-01-14 Hans Brammer Cannabispräparat
MX376247B (es) * 2014-08-11 2025-03-07 Perora Gmbh Formulacion que comprende particulas.
US20190201350A1 (en) 2016-08-15 2019-07-04 Corr-Jensen Inc. Time release of fat-soluble actives
DE102019100483A1 (de) * 2019-01-10 2020-07-16 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm

Also Published As

Publication number Publication date
AU2020365443A1 (en) 2022-06-02
IL292018A (en) 2022-06-01
JP2022553653A (ja) 2022-12-26
CA3157654A1 (en) 2021-04-22
BR112022006643A2 (pt) 2022-07-12
US20240139215A1 (en) 2024-05-02
EP3808341A1 (de) 2021-04-21
EP4045014A1 (de) 2022-08-24
CN114945353A (zh) 2022-08-26
WO2021074403A1 (de) 2021-04-22

Similar Documents

Publication Publication Date Title
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
WO2020016659A3 (en) Multiparticulate formulations of cannabinoids
MX2020006957A (es) Composicion de liberacion modificada que comprende un cannabinoide.
EP4360651A3 (en) Glp-1 compositions and uses thereof
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
TW200640501A (en) Crush resistant delayed-release dosage forms
MX2022004523A (es) Formulaciones de liberacion controlada para sustancias fisiologicamente activas altamente lipofilicas.
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EA201792345A1 (ru) Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
MX2020012265A (es) Goma de mascar en tabletas adecuada para ingredientes farmaceuticos activos.
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP3530123A4 (en) FEED COMPOSITION WITH BACILIUS SUBTILUS STEM AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF ACUTE HEPATOPANIC NECROSIS OR WHITE SPOT SYNDROME
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
PH12022551300A1 (en) Oral products with controlled release
MX2021015912A (es) Metodo de composiciones insecticidas de doble actividad.
UA102547C2 (uk) Тверда фармацевтична композиція
PH12019500137A1 (en) Vaginal composition comprising a combination of estrogen and vitamin d
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
MX2022006502A (es) Composiciones farmaceuticas.
MX2021002515A (es) Estabilizacion de forma de dosis a base de lipidos solidos o semisolidos a traves de curar y adicionar surfactantes de bajo hlb.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2022004522A (es) Formulaciones de liberacion controlada de sustancias fisiologicamente activas altamente lipofilicas.
WO2019142062A3 (en) Synergistic herbal composition with anti-proliferative activity
WO2019203755A3 (en) A solid oral dosage form comprising linagliptin